Dilated cardiomyopathy screening: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
Screening is only recommended in individuals who have a family history of Familial Dilated Cardiomyopathy (FDC). | Screening is only recommended in individuals who have a family history of Familial Dilated Cardiomyopathy (FDC). | ||
* In case of 2 or 3 family members affected with primary DCM, | * In case of 2 or 3 family members affected with primary DCM, screening of first degree relatives, using electrocardiogram and echocardiography allows the identification of FDC according to guidelines from the Cardiac Genetic Diseases Council. | ||
*FDC can be identified in 20–35% of DCM cases, while the remaining are classified as ‘idiopathic’ | *FDC can be identified in 20–35% of DCM cases, while the remaining are classified as ‘idiopathic’.<ref name="pmid21885340">{{cite journal| author=Fatkin D, members of the CSANZ Cardiac Genetic Diseases Council Writing Group| title=Guidelines for the diagnosis and management of familial dilated cardiomyopathy. | journal=Heart Lung Circ | year= 2011 | volume= 20 | issue= 11 | pages= 691-3 | pmid=21885340 | doi=10.1016/j.hlc.2011.07.008 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21885340 }}</ref> | ||
*FCD is primarily an autosomal dominant disease; however, cases with autosomal recessive or X-linked inheritance have been recognized. | *FCD is primarily an autosomal dominant disease; however, cases with autosomal recessive or X-linked inheritance have been recognized. | ||
* Genetic studies have revealed an underlying genetic mutation in 30 to 40% of patients with FCD. | * Genetic studies have revealed an underlying genetic mutation in 30 to 40% of patients with FCD.<ref name="pmid23281406">{{cite journal| author=McNally EM, Golbus JR, Puckelwartz MJ| title=Genetic mutations and mechanisms in dilated cardiomyopathy. | journal=J Clin Invest | year= 2013 | volume= 123 | issue= 1 | pages= 19-26 | pmid=23281406 | doi=10.1172/JCI62862 | pmc=3533274 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23281406 }}</ref> | ||
* About 40 genes are currently included in genetic testing; however, mutations in >60 other genes have been linked to FCD, but are yet to be included. | * About 40 genes are currently included in genetic testing; however, mutations in >60 other genes have been linked to FCD, but are yet to be included. | ||
*A cohort study by Haas et al. showed that the genetic mutations in FCD overlap with other cardiomyopathies, highlighting the value of genetic testing in different types of cardiomyopathy.<ref name="pmid25163546">{{cite journal| author=Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R et al.| title=Atlas of the clinical genetics of human dilated cardiomyopathy. | journal=Eur Heart J | year= 2015 | volume= 36 | issue= 18 | pages= 1123-35a | pmid=25163546 | doi=10.1093/eurheartj/ehu301 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25163546 }}</ref> | |||
*A cohort study by Haas et al. showed that the genetic mutations in FCD overlap with other cardiomyopathies, highlighting the value of genetic testing in different types of cardiomyopathy. | * Current studies are focusing on the role of multiple mutations, enhancer region mutations, copy number variation, and intronic variants.<ref name="pmid27547593">{{cite journal| author=Sweet M, Taylor MR, Mestroni L| title=Diagnosis, prevalence, and screening of familial dilated cardiomyopathy. | journal=Expert Opin Orphan Drugs | year= 2015 | volume= 3 | issue= 8 | pages= 869-876 | pmid=27547593 | doi=10.1517/21678707.2015.1057498 | pmc=4988677 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27547593 }}</ref> | ||
* Current studies are focusing on the role of multiple mutations, enhancer region mutations, copy number variation, and intronic variants. | |||
==References== | ==References== | ||
Revision as of 17:36, 4 December 2019
|
Dilated cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dilated cardiomyopathy screening On the Web |
|
American Roentgen Ray Society Images of Dilated cardiomyopathy screening |
|
Risk calculators and risk factors for Dilated cardiomyopathy screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdelrahman Ibrahim Abushouk, MD[2]
Overview
The current guidelines recommend screening for dilated cardiomyopathy in individuals with 2 or 3 family members with primary dilated cardiomyopathy. Screening can be performed using electrocardiograms and echocardiography to measure the size and function of the left ventricle. An underlying genetic mutation in the 40 genes (currently assessed in FCD genetic testing) can be detected in 30 to 40% of FCD patients.
Screening
Screening is only recommended in individuals who have a family history of Familial Dilated Cardiomyopathy (FDC).
- In case of 2 or 3 family members affected with primary DCM, screening of first degree relatives, using electrocardiogram and echocardiography allows the identification of FDC according to guidelines from the Cardiac Genetic Diseases Council.
- FDC can be identified in 20–35% of DCM cases, while the remaining are classified as ‘idiopathic’.[1]
- FCD is primarily an autosomal dominant disease; however, cases with autosomal recessive or X-linked inheritance have been recognized.
- Genetic studies have revealed an underlying genetic mutation in 30 to 40% of patients with FCD.[2]
- About 40 genes are currently included in genetic testing; however, mutations in >60 other genes have been linked to FCD, but are yet to be included.
- A cohort study by Haas et al. showed that the genetic mutations in FCD overlap with other cardiomyopathies, highlighting the value of genetic testing in different types of cardiomyopathy.[3]
- Current studies are focusing on the role of multiple mutations, enhancer region mutations, copy number variation, and intronic variants.[4]
References
- ↑ Fatkin D, members of the CSANZ Cardiac Genetic Diseases Council Writing Group (2011). "Guidelines for the diagnosis and management of familial dilated cardiomyopathy". Heart Lung Circ. 20 (11): 691–3. doi:10.1016/j.hlc.2011.07.008. PMID 21885340.
- ↑ McNally EM, Golbus JR, Puckelwartz MJ (2013). "Genetic mutations and mechanisms in dilated cardiomyopathy". J Clin Invest. 123 (1): 19–26. doi:10.1172/JCI62862. PMC 3533274. PMID 23281406.
- ↑ Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R; et al. (2015). "Atlas of the clinical genetics of human dilated cardiomyopathy". Eur Heart J. 36 (18): 1123–35a. doi:10.1093/eurheartj/ehu301. PMID 25163546.
- ↑ Sweet M, Taylor MR, Mestroni L (2015). "Diagnosis, prevalence, and screening of familial dilated cardiomyopathy". Expert Opin Orphan Drugs. 3 (8): 869–876. doi:10.1517/21678707.2015.1057498. PMC 4988677. PMID 27547593.